Novartis AG's Leukemia Drug CTL01 Clears Cancer In 90 Percent Of Patients

Novartis Announces CTL019 Data Published In NEJM Demonstrating Efficacy In Certain Patients With Acute Lymphoblastic Leukemia - Preliminary study results show 27 of 30 pediatric and adult patients with relapsed/refractory ALL experienced complete remissions with personalized cell therapy, CTL0191 - Largest published cohort to date for CTL019, which served as the basis for recent Breakthrough Therapy designation from the FDA2 - Sustained remissions of up to two years in r/r ALL patients with six-month event-free survival of 67% and overall survival of 78%1 - Novartis and Penn have exclusive global collaboration to research, develop and commercialize CAR T cell therapies for the investigational treatment of cancers ) today announced preliminary results from two pilot clinical trials published in The New England Journal of Medicine evaluating the efficacy and safety of CTL019 in patients ... (more)

http://ift.tt/1rduubO